1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (612) 626-0665.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
Article first published online: 30 NOV 2007
DOI: 10.1002/cncr.23164
Copyright © 2007 American Cancer Society
Additional Information
How to Cite
Downs, L. S., Judson, P. L., Argenta, P. A., Ghebre, R., Geller, M. A., Bliss, R. L., Boente, M. P., Nahhas, W. A., Abu-Ghazaleh, S. Z., Chen, M. D. and Carson, L. F. (2008), A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer, 112: 331–339. doi: 10.1002/cncr.23164
Publication History
- Issue published online: 4 JAN 2008
- Article first published online: 30 NOV 2007
- Manuscript Accepted: 10 AUG 2007
- Manuscript Revised: 3 AUG 2007
- Manuscript Received: 13 JUN 2007
Funded by
- Celgene Corporation
REFERENCES
- 1American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society; 2006.
- 2,,. Effects of thalidomide and related metobolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997; 64: 971–978.
- 3,,. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med. 1993; 177: 1675–1680.
- 4,,. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002; 53: 629–657.
- 5,,, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor-α inhibitory activity. Mol Med. 1996; 2: 506–515.
- 6,,,. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998; 187: 1885–1892.
- 7,,. Thalidomide selectively modulates the density of cell surface molecules, involved in the adhesion cascade. Immunopharmocology. 1996; 31: 213–221.
- 8,,, et al. Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res. 2005; 65: 10464–10471.
- 9,,, et al. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999; 44: 411–416.
- 10. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004; 9: 33–42.
- 11,,, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–216.
- 12,. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7: 437–443.
- 13,,,. Thalidomide treatment of ovarian carcinoma—a preliminary analysis. Presented at the 29th Annual Meeting of the Western Association of Gynecological Oncologists, May 24–27, 2000, Monterey, California.
- 14,,, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996; 14: 3056–3061.
- 15,. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549–556.
- 16,. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. Stat Med. 2001; 20: 1575–1589.Direct Link:
- 17,,. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol. 2007; 82: 855–857.Direct Link:
- 18,,. Thalidomide and thrombosis. Thromb Haemost. 2007; 97: 1031–1036.
- 19,,, et al. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol. 2006; 103: 919–923.
- 20,,, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000; 82: 812–817.
- 21,,, et al. Thalidomide as an antiangiogenic agent in relapsed gliomas. J Neurooncol. 2001; 51: 41–45.
- 22,,, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2001; 54: 31–38.
- 23,,, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high grade gliomas. J Clin Oncol. 2003; 21: 2299–2304.
- 24,,, et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003; 24: 822–827.
- 25,,, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001; 7: 1888–1893.
- 26,,, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001; 28(4 Suppl 15 ): 62–66.
- 27,,, et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol. 2005; 125: 201–206.